Lemborexant was approved by the U.S. Food and Drug Administration (FDA)  on December 20, 2019. This medication belongs to the orexin receptor antagonist class

Lemborexant is used to treat insomnia.

Lemborexant is typically administered orally shortly before bedtime. Individual factors and the severity of insomnia determine the recommended dosage. It should be taken without food, and alcohol or other sedatives should be avoided to prevent excessive drowsiness and impaired coordination.

Lemborexant use can result in various side effects. Common side effects include headache, somnolence (excessive sleepiness), dizziness, fatigue, abnormal dreams, and upper respiratory tract infections. Serious but less common side effects encompass sleep-related behaviors like sleep-driving and sleep-eating, allergic reactions such as rash and swelling, and the potential emergence of depression and suicidal thoughts. 

Several important warnings accompany lemborexant use. It may induce complex sleep behaviors like sleep-driving and sleep-eating, posing risks to safety. Allergic reactions are rare but serious, warranting immediate medical attention if symptoms such as rash, swelling, or difficulty breathing occur. There's a potential for the emergence of depression and suicidal thoughts, requiring vigilant monitoring of mood and behavior

Combining lemborexant with other CNS depressants, like alcohol or opioids, can enhance sedation and should be avoided. Long-term use should be periodically reassessed, and potential cognitive effects, including memory impairment, should be considered. Overall, consultation with a healthcare provider is paramount to navigate these warnings and ensure safe usage.

Lemborexant potential to induce drowsiness and impair cognitive and motor skills demands caution when engaging in activities such as driving or operating machinery. Alcohol and other sedatives should be avoided, as combined with this medication can intensify sedation. Individuals with liver impairment need careful monitoring and potential dose adjustments due to the medication's metabolism. Its safety during pregnancy and breastfeeding is uncertain, necessitating a thorough discussion with a healthcare provider before use. Elderly individuals might be more sensitive to the drug's effects and require lower dosages. As with any medication, a comprehensive review of medical history and current medications is vital to ensure that this medication is used safely and effectively.

1. Rosenberg et al.; Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies; Neuropsychiatric Disease and Treatment 2021:17 2549–2566; [Published on August 2021]; [Accessed on 28th August 2023]; https://www.dovepress.com/getfile.php?fileID=72977
2. Eisai Inc, US Food and Drug Administration, [Issued on  March 2022], [Accessed on 28th August 2023], https://www.dayvigo.com/-/media/Files/DAYVIGO/PDF/prescribing-information.pdf?hash=29123669-6b3b-4728-ab27-b2e49ef34788
3. Yardley J, Kärppä M, Inoue Y et al. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Medicine; [Published on April 2021]; [Accessed on 28th August 2023]; https://www.sciencedirect.com/science/article/pii/S1389945721000654

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.